Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | Buy → Hold | Jefferies | |
| 11/4/2024 | Outperform → Perform | Oppenheimer | |
| 11/4/2024 | $15.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 6/26/2023 | $17.00 | Outperform | Oppenheimer |
| 8/17/2021 | $36.00 → $22.00 | Outperform | Oppenheimer |
Jefferies downgraded ESSA Pharma from Buy to Hold
Oppenheimer downgraded ESSA Pharma from Outperform to Perform
Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Co
SOUTH SAN FRANCISCO, Calif and VANCOUVER, Canada, Aug. 6, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, following the Company's receipt of an order from the Supreme Court of British Columbia (the "Court") on August 5, 2025, authorizing a reduction in the capital of the common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") and concurrent distribution to the Shareholders, the board of directors of the Company (the "Board") has approved a return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the Shareholders as part of the discontinuance and win
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with its previously announced business combination agreement with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"), the Company intends to apply to the Supreme Court of British Columbia (the "Court") on August 5, 2025 for (i) an interim order authorizing the holding of a special meeting to consider and approve the Transaction (the "Interim Order") and (ii) for an order authorizi
DEFA14A - ESSA Pharma Inc. (0001633932) (Filer)
8-K - ESSA Pharma Inc. (0001633932) (Filer)
10-Q - ESSA Pharma Inc. (0001633932) (Filer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg
SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that, in connection with the Company's recently announced return of capital distribution in the aggregate amount of US$80,000,000 (the "Distribution") to the holders of common shares of the Company ("Common Shares" and the holders of such Common Shares, the "Shareholders") as part of the discontinuance and winding-up of the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Co
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"). XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotechnology royalty aggregator, is acting as the structuring agent and will provide financing to Xeno for this Transaction. Under the terms of the Business Combi
Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)